Kaiser Permanente Roseville

Clinical research site in Roseville, California · 1600 EUREKA RD, ROSEVILLE, CA 95661-3027 · (916) 784-5880

As of September 2026, 34 paid clinical trials are recruiting at Kaiser Permanente Roseville in Roseville, California. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Lung Non-Small Cell Carcinoma and Stage IIIB Lung Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

New trial at Kaiser Permanente Roseville? We'll email you when one opens.

Recruiting clinical trials at Kaiser Permanente Roseville (34)

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

for Clostridoides Difficile Associated Disease

140 locations incl. Athens

Sponsor: Pfizer

Sex: All·Age: 65+·Accepts healthy volunteers

Code: NCT07282665·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

82 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

for Mature B-Cell Non-Hodgkin Lymphoma

10 locations incl. Birmingham

Sponsor: Hoffmann-La Roche

Sex: All·Age: 6 Months - 30

Code: NCT05533775·Phase 1, Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

623 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1100 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

915 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

779 locations incl. Issaquah

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

632 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

593 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for Advanced Lung Non-Squamous Non-Small Cell Carcinoma

327 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04181060·Phase 3·Recruiting·Listed Nov 2019

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

655 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

443 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia

155 locations incl. Antioch

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18 - 39

Code: NCT03150693·Phase 3·Recruiting·Listed May 2017

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

481 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

338 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

330 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

374 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for Lung Non-Small Cell Carcinoma

266 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06498635·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

206 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

216 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

172 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

142 locations incl. Dublin

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

238 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for Castration-Sensitive Prostate Carcinoma

195 locations incl. Tucson

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male·Age: 18+

Code: NCT06931340·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

950 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

372 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

399 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

73 locations incl. Dublin

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06029270·Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

588 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting·Listed May 2021

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

381 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for Breast Carcinoma

464 locations incl. Fairbanks

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 18+

Code: NCT06418204·Recruiting·Listed May 2024

Apply to this trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for Castration Levels of Testosterone

294 locations incl. Gilbert

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT03678025·Phase 3·Recruiting·Listed Sep 2018

Apply to this trial

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

for Prostate Cancer

46 locations incl. Antioch

Sponsor: Canadian Cancer Trials Group

Sex: Male·Age: 18+

Code: NCT06235697·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

Get new-trial alerts for Kaiser Permanente Roseville

We'll email you whenever a new clinical trial starts recruiting at this research site in Roseville, CA. Unsubscribe anytime.

More research sites in Roseville

Kaiser Permanente-Roseville (31 trials)
Sutter Roseville Medical Center (23 trials)
Sutter Cancer Centers Radiation Oncology Services-Roseville (15 trials)
The Permanente Medical Group-Roseville Radiation Oncology (10 trials)
Kaiser Permanente Roseville Medical Center (3 trials)
Kaiser Permanente (2 trials)
Roseville Medical Plaza Care Center (2 trials)
Sutter Medical Center, Sacramento Infusion Center at Roseville (2 trials)
Kaiser Permanente - Roseville (2 trials)
ClearVue Eye Care (1 trial)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Roseville, CA · California clinical trials